← Eichor
Study identifier: NCT06591286 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control

Condition: Diabetes Mellitus, Type 2  ·  Sponsor: Shanghai 6th People's Hospital

PhaseNA
Planned participants150
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.

This description comes directly from the study's public registry record.

Talk to the study team

Shiyun Wang, Dr.  ·  +86 21 2405 8570  ·  rhyme2008@alumni.sjtu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai 6th People's HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06591286